Skip to main content
. 2023 Mar 1;20(3):450–455. doi: 10.1513/AnnalsATS.202207-648OC

Table 1.

Characteristics and demographics of patients with central sleep apnea or obstructive sleep apnea

  CSA (n = 2,961) OSA (n = 1,487,353)
Age, M (SD) 61.8 (15.6) 56.7 (13.9)
 <65 yr, n (%) 1,477 (49.9) 1,003,487 (67.5)
 ⩾65 yr, n (%) 1,484 (50.1) 483,866 (32.5)
Body mass index, M (SD) 31.2 (6.2) 33.5 (6.2)
 <18.5 22 (0.7) 3,772 (0.3)
 ⩾18.5 to <30 1,342 (45.3) 453,195 (30.5)
 ⩾30 1,597 (53.9) 1,030,386 (69.3)
Race, n (%)    
 White 2,325 (78.5) 1,058,902 (71.2)
 Black 393 (13.3) 298,392 (20.1)
 Other 243 (8.2) 130,059 (8.7)
Sex (male), n (%) 2,834 (95.7) 1,389,393 (93.4)
Ethnicity (Hispanic), n (%) 150 (5.1) 117,779 (7.9)
Comorbidity    
 CCI, M (SD) 1.8 (2.3) 1.6 (2.1)
  CCI ⩾2, n (%) 1,137 (38.4) 6,846 (37.1)
 Myocardial infarction, n (%) 138 (4.7) 37,615 (2.5)
 Heart failure, n (%) 470 (15.9) 99,919 (6.7)
 Peripheral vascular disease, n (%) 295 (10.0) 75,627 (5.1)
 Cerebrovascular disease, n (%) 280 (9.5) 73,510 (4.9)
 Dementia, n (%) 96 (3.2) 12,385 (0.8)
 Chronic obstructive pulmonary disease, n (%) 618 (20.9) 276,346 (18.6)
 Connective tissue disease, n (%) 45 (1.5) 18,535 (1.2)
 Peptic ulcer disease, n (%) 25 (0.8) 11,434 (0.8)
 Mild liver disease, n (%) 121 (4.1) 37,880 (2.5)
 Diabetes mellitus without complication, n (%) 866 (29.2) 425,423 (28.6)
 Diabetes mellitus with end-organ damage, n (%) 338 (11.4) 137,269 (9.2)
 Hemiplegia, n (%) 46 (1.6) 7,856 (0.5)
 Moderate to severe chronic kidney disease, n (%) 375 (12.7) 94,393 (6.3)
 Solid tumor (localized), n (%) 241 (8.1) 89,223 (6.0)
 Moderate to severe liver disease, n (%) 16 (0.5) 3,795 (0.3)
 Solid tumor (metastatic), n (%) 28 (0.9) 5,127 (0.3)
 Acquired immunodeficiency syndrome, n (%) 7 (0.2) 4,657 (0.3)

Definition of abbreviations: CCI = Charlson Comorbidity Index; CSA = central sleep apnea; M (SD) = mean (standard deviation); OSA = obstructive sleep apnea.